Decitabine Maintains Hematopoietic Precursor Self-Renewal by Preventing Repression of Stem Cell Genes by a Differentiation-Inducing Stimulus
Year: 2010
Type: article
Abstract: The cytosine analogue decitabine alters hematopoietic differentiation. For example, decitabine treatment increases self-renewal of normal hematopoietic stem cells. The mechanisms underlying decitabine-induced shifts in differentiation are poorly understood, but likely relate to the ability of decitabine to deplete the chromatin-modifying enzyme DNA methyltransferase 1 (DNMT1), which plays a central role in transcription repression. HOXB4 is a transcription factor that promotes hematopoietic stem cell self-renewal. In hematopoietic precursors induced to differentiate by the lineage-specifying transcription factor Pu.1 or by the cytokine granulocyte-colony stimulating factor, there is rapid repression of HOXB4 and other stem cell genes. Depletion of DNMT1 using shRNA or decitabine prevents HOXB4 repression by Pu.1 or granulocyte-colony stimulating factor and maintains hematopoietic precursor self-renewal. In contrast, depletion of DNMT1 by decitabine 6 hours after the differentiation stimulus, that is, after repression of HOXB4 has occurred, augments differentiation. Therefore, DNMT1 is required for the early repression of stem cell genes, which occurs in response to a differentiation stimulus, providing a mechanistic explanation for the observation that decitabine can maintain or increase hematopoietic stem cell self-renewal in the presence of a differentiation stimulus. Using decitabine to deplete DNMT1 after this early repression phase does not impair progressive differentiation.
Source: Molecular Cancer Therapeutics
Institutions: Cleveland Clinic, University of Chicago
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: U.S. Department of Defense, Foundation for the National Institutes of Health, Abraham J. and Phyllis Katz Foundation, National Institutes of Health, U.S. Food and Drug Administration, National Heart, Lung, and Blood Institute, National Cancer Institute, National Center for Research Resources
Awards: Chicago Comprehensive Sickle Cell Center: Basic & Translational Research Program, Optimizing decitabine regimen + formulation for nonDNA damaging DNMT1 depletion, G481402874, G5169329980, Laser Scanning Confocal Microscope, Training/Research Center-Bone Marrow Failure Syndromes, Predisposition to chromosomal alterations in MDS
OpenAlex ID: W2166833866
